Recently, 2021 Healthy China-The First China OTC Conference and China Traditional Chinese Medicine Promotion Conference was held in Guangzhou.
During the meeting, the China Non-prescription Drug Association released a number of lists such as the "2021 Comprehensive Statistical Ranking of Non-prescription Drug Products in China". Awarded "China's non-prescription drug gold single product".
It is reported that Lianhua Qingwen Capsule has been on the market for more than ten years and has covered more than 300,000 hospitals and pharmacies across the country.
In 2011, Lianhua Qingwen won the second prize of the National Science and Technology Progress Award; in 2016, it began to carry out Phase II clinical trials in the United States, becoming the first anti-flu Chinese medicine to enter the US FDA clinical research; in 2020, Lianhua Qingwen Capsules were selected as " Annual Chinese OTC Gold Variety".
Lianhua Qingwen Capsule is an innovative Chinese medicine developed under the guidance of the theory of collateral diseases in Chinese medicine. It is created by the research results of improving immunity and other traditional Chinese medicines.
Up to now, Lianhua Qingwen has been approved for listing in more than 20 countries and regions including Canada, Russia, Kuwait, Singapore, etc., and has initiated registration in more than 30 countries around the world. It has gained international recognition and its international brand influence has been extremely strong. Great improvement.